NovoCure Limited (NVCR) Spending and interest coverage
- R&D / revenue · 12 months: Value 32.14%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 18.47%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 32.14% | Research and development expense / revenue. Period ending 2026-06-30. $224.72M ÷ $699.19M × 100 ≈ 32.14% |
| Stock-based compensation / revenue · 12 months | 18.47% | Share-based compensation / revenue. Period ending 2026-06-30. $129.16M ÷ $699.19M × 100 ≈ 18.47% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 224.72M USD | Research and Development Expense |
| Revenue | 699.19M USD | |
| Stock-based compensation | 129.16M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -154.40M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $224.72M | $699.19M | $129.16M | $-154.40M | (m) | 32.14% | 18.47% | (m) | (m) |
| 2026-03-31 | $229.10M | $674.41M | $138.29M | $-183.35M | (m) | 33.97% | 20.51% | (m) | (m) |
| 2025-12-31 | $224.54M | $655.35M | $104.83M | $-153.80M | $22.22M | 34.26% | 16.00% | -6.92× | Reported |
| 2025-09-30 | $214.85M | $642.27M | $147.77M | $-176.71M | (m) | 33.45% | 23.01% | (m) | (m) |
| 2025-06-30 | $212.70M | $630.16M | $149.82M | $-172.78M | (m) | 33.75% | 23.77% | (m) | (m) |
| 2025-03-31 | $211.82M | $621.71M | $155.50M | $-166.84M | (m) | 34.07% | 25.01% | (m) | (m) |
| 2024-12-31 | $209.65M | $605.22M | $160.03M | $-170.50M | $11.66M | 34.64% | 26.44% | -14.62× | Reported |
| 2024-09-30 | $212.74M | $577.74M | $114.72M | $-158.91M | (m) | 36.82% | 19.86% | (m) | (m) |
| 2024-06-30 | $214.48M | $549.96M | $109.70M | $-185.06M | (m) | 39.00% | 19.95% | (m) | (m) |
| 2024-03-31 | $214.96M | $525.66M | $110.61M | $-214.14M | (m) | 40.89% | 21.04% | (m) | (m) |
| 2023-12-31 | $223.06M | $509.34M | $115.61M | $-232.87M | $4.91M | 43.79% | 22.70% | -47.47× | Reported |
| 2023-09-30 | $223.57M | $503.98M | $127.95M | $-224.13M | (m) | 44.36% | 25.39% | (m) | (m) |
| 2023-06-30 | $221.91M | $507.66M | $127.91M | $-190.50M | (m) | 43.71% | 25.20% | (m) | (m) |
| 2023-03-31 | $223.56M | $522.48M | $120.99M | $-148.97M | (m) | 42.79% | 23.16% | (m) | (m) |
| 2022-12-31 | $206.09M | $537.84M | $106.95M | $-89.52M | $8.11M | 38.32% | 19.89% | -11.03× | Reported |
| 2022-09-30 | $208.20M | $542.62M | $99.57M | $-69.94M | (m) | 38.37% | 18.35% | (m) | (m) |
| 2022-06-30 | $204.38M | $545.23M | $99.02M | $-53.88M | (m) | 37.49% | 18.16% | (m) | (m) |
| 2022-03-31 | $197.62M | $537.88M | $101.08M | $-45.05M | (m) | 36.74% | 18.79% | (m) | (m) |
| 2021-12-31 | $201.30M | $535.03M | $94.90M | $-44.33M | $8.84M | 37.62% | 17.74% | -5.02× | Reported |
| 2021-09-30 | $188.37M | $545.77M | $92.78M | $-8.84M | (m) | 34.52% | 17.00% | (m) | (m) |
| 2021-06-30 | $173.05M | $544.83M | $87.14M | $14.73M | (m) | 31.76% | 15.99% | (m) | (m) |
| 2021-03-31 | $152.66M | $527.23M | $78.03M | $33.69M | (m) | 28.95% | 14.80% | (m) | (m) |
| 2020-12-31 | $132.01M | $494.37M | $75.72M | $30.40M | $18.05M | 26.70% | 15.32% | 1.68× | Reported |
| 2020-09-30 | $111.75M | $449.65M | $70.14M | $18.46M | (m) | 24.85% | 15.60% | (m) | (m) |
| 2020-06-30 | $97.70M | $409.05M | $64.36M | $7.29M | (m) | 23.88% | 15.73% | (m) | (m) |
| 2020-03-31 | $87.23M | $379.84M | $59.32M | $1.82M | (m) | 22.97% | 15.62% | (m) | (m) |
| 2019-12-31 | $79.00M | $351.32M | $52.42M | $-914.00K | $14.64M | 22.49% | 14.92% | -0.06× | Reported |
| 2019-09-30 | $70.30M | $321.76M | $48.36M | $-9.73M | (m) | 21.85% | 15.03% | (m) | (m) |
| 2019-06-30 | $64.60M | $294.45M | $44.50M | $-18.83M | (m) | 21.94% | 15.11% | (m) | (m) |
| 2019-03-31 | $56.51M | $269.25M | $40.98M | $-27.11M | (m) | 20.99% | 15.22% | (m) | (m) |
| 2018-12-31 | $50.57M | $248.07M | $39.85M | $-33.67M | $16.91M | 20.39% | 16.06% | -1.99× | Reported |
| 2018-09-30 | $45.59M | $232.06M | $35.56M | $-29.51M | (m) | 19.65% | 15.32% | (m) | (m) |
| 2018-06-30 | $41.79M | $217.41M | $33.71M | $-30.19M | (m) | 19.22% | 15.51% | (m) | (m) |
| 2018-03-31 | $39.80M | $194.27M | $31.07M | $-38.63M | (m) | 20.48% | 16.00% | (m) | (m) |
| 2017-12-31 | $38.10M | $177.03M | $27.12M | $-39.33M | $11.69M | 21.52% | 15.32% | -3.36× | Reported |
| 2017-09-30 | $36.53M | $153.61M | $26.18M | $-52.70M | (m) | 23.78% | 17.04% | (m) | (m) |
| 2017-06-30 | $37.49M | $125.17M | $23.18M | $-75.05M | (m) | 29.95% | 18.52% | (m) | (m) |
| 2017-03-31 | $39.43M | $104.72M | $21.24M | $-96.75M | (m) | 37.66% | 20.29% | (m) | (m) |
| 2016-12-31 | $41.47M | $82.89M | $22.14M | $-115.32M | $7.32M | 50.03% | 26.71% | -15.76× | Reported |
| 2016-09-30 | $43.84M | $65.03M | $21.21M | $-128.05M | (m) | 67.42% | 32.61% | (m) | (m) |
| 2016-06-30 | $43.82M | $52.31M | $18.51M | $-124.02M | (m) | 83.77% | 35.38% | (m) | (m) |
| 2016-03-31 | $45.27M | $40.93M | $15.50M | $-113.99M | (m) | 110.59% | 37.88% | (m) | (m) |
| 2015-12-31 | $43.75M | $33.09M | $11.86M | $-104.00M | $3.23M | 132.22% | 35.84% | -32.15× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $40.38M | $15.49M | $4.62M | $-80.16M | $287.00K | 260.69% | 29.85% | -279.29× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $34.80M | $10.36M | $5.12M | $-64.46M | $12.82M | 335.91% | 49.43% | -5.03× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |